The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck

Basit Öğe Kaydı
dc.authoridFayda, Merdan/0000-0002-2800-5327
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidFayda, Merdan/AAF-7370-2019
dc.authorwosidFayda, Merdan/F-5092-2012
dc.authorwosidBilici, Ahmet/E-2062-2018
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorUygun, Kazim
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKaragol, Hakan
dc.contributor.authorCaloglu, Murat
dc.contributor.authorCicin, Irfan
dc.contributor.authorAksu, Gorkem
dc.contributor.authorFayda, Merdan
dc.date.accessioned2024-06-12T11:03:52Z
dc.date.available2024-06-12T11:03:52Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description31st Congress of the European-Society-for-Medical-Oncology -- SEP 29-OCT 03, 2006 -- Istanbul, TURKEYen_US
dc.description.abstractSeveral studies have shown that the concurrent administration of chemotherapy (CHT) and radiotherapy (RT) is superior to RT alone in patients with inoperable non-metastatic squamous cell carcinoma of the head and neck (InSCCHN). We compared the efficacy and safety profile of RT and concurrent cisplatin CHT given in two different schedules to patients with previously untreated InSCCHN. Fifty patients with previously untreated InSCCHN admitted to our oncology department were included in the study. Thirty of 50 (60%) patients with a younger age or good performance status (PS) (ECOG 0-1) received cisplatin 100 mg/m(2) on a 21-day schedule (group A). Other 20 (40%) patients with older age or poor PS (ECOG 2) received cisplatin 40 mg/m(2) on a 7-day schedule (group B). Each of the 50 patients received concurrent conventional dose RT according to primer tumor location. The median follow-up is 12 months for group A and 12.5 months for group B. Twenty-eight (93.3%) patients in group A and 18 (90%) in group B were evaluable for response. The complete response rate was 50% in group A and 40% in group B (P > 0.05). The objective response rate was 92% in group A and 90% in group B (P > 0.05). All grade 3-4 toxic events were seen in 16 (53.3%) of group A patients and 8 (40%) of group B patients (P > 0.05). Comparison between two treatment modalities appears to result in statistically similar response rates and adverse event profile. A randomized phase III trial is required to confirm the safety and efficacy of weekly cisplatin therapy in patients with poor PS and/or older age at diagnosis.en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.identifier.doi10.1007/s00280-008-0911-7
dc.identifier.endpage605en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue3en_US
dc.identifier.pmid19123002en_US
dc.identifier.scopus2-s2.0-67349144673en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage601en_US
dc.identifier.urihttps://doi.org/10.1007/s00280-008-0911-7
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21811
dc.identifier.volume64en_US
dc.identifier.wosWOS:000267038900018en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer Chemotherapy And Pharmacologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInoperable Head And Neck Canceren_US
dc.subjectSquamous Cellen_US
dc.subjectWeekly Cisplatinen_US
dc.subjectThree Weeklyen_US
dc.subjectCisplatinen_US
dc.subjectConcurrent Chemoradiotherapyen_US
dc.subjectLocally Advanced Headen_US
dc.subjectRadiation-Therapyen_US
dc.subjectRandomized-Trialen_US
dc.subjectPhase-Iien_US
dc.subjectCanceren_US
dc.subjectOncologyen_US
dc.subjectEortcen_US
dc.titleThe comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and necken_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu